In the lung, cystic fibrosis (CF) represents an attractive target for the design of RNA-based therapeutics, with mutations of the cystic fibrosis transmembrane receptor (CFTR) being the causative factor in the development of the disease (Riordan et al., 1989; Ong and Ramsey, 2023). The gene discussed is CFTR; the disease is cystic fibrosis.